Global Blood's voxelotor shows lower response rate in 24-week sickle cell readout

Global Blood Therapeutics Inc. (NASDAQ:GBT) reported updated Phase IIa data in sickle cell disease patients showing that voxelotor (formerly GBT440) led to a lower hemoglobin response rate than

Read the full 280 word article

User Sign In